In fiscal year 2023, the value of Astellas Pharma's research and development expenditures amounted to more than 294 billion Japanese yen, the highest number of the past decade. Within the observed period, R&D spending increased steadily almost every year, starting at approximately 206 billion yen in fiscal 2014. The priority areas of Astellas research and development include infectious diseases, diabetes, and gastrointestinal diseases.
Research and development (R&D) expenses of Astellas Pharma Inc. from fiscal year 2014 to 2023
(in billion Japanese yen)
fiscal year 2014 to 2023; the company's fiscal year starts on April 1 of the stated year and ends on March 31 of the following year
Special properties
consolidated data
Supplementary notes
Astellas Pharma Inc. has adopted International Financial Reporting Standards (IFRS) since the fiscal year ended March 31, 2014. Figures up to fiscal year ended March 31 2014, are based on Japanese generally accepted accounting principles (J-GAAP). Figures prior to FY 2021 come from the previous reporting.
100 Japanese yen equal 0.64 U.S. dollars or 0.6 euros as of May 2024.Â
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Astellas. (April 25, 2024). Research and development (R&D) expenses of Astellas Pharma Inc. from fiscal year 2014 to 2023 (in billion Japanese yen) [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/825655/astellas-pharma-research-and-development-expenses/
Astellas. "Research and development (R&D) expenses of Astellas Pharma Inc. from fiscal year 2014 to 2023 (in billion Japanese yen)." Chart. April 25, 2024. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/825655/astellas-pharma-research-and-development-expenses/
Astellas. (2024). Research and development (R&D) expenses of Astellas Pharma Inc. from fiscal year 2014 to 2023 (in billion Japanese yen). Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/825655/astellas-pharma-research-and-development-expenses/
Astellas. "Research and Development (R&d) Expenses of Astellas Pharma Inc. from Fiscal Year 2014 to 2023 (in Billion Japanese Yen)." Statista, Statista Inc., 25 Apr 2024, https://www-statista-com.ezproxy.canberra.edu.au/statistics/825655/astellas-pharma-research-and-development-expenses/
Astellas, Research and development (R&D) expenses of Astellas Pharma Inc. from fiscal year 2014 to 2023 (in billion Japanese yen) Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/825655/astellas-pharma-research-and-development-expenses/ (last visited November 10, 2024)
Research and development (R&D) expenses of Astellas Pharma Inc. from fiscal year 2014 to 2023 (in billion Japanese yen) [Graph], Astellas, April 25, 2024. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/825655/astellas-pharma-research-and-development-expenses/
